https://retacompare.com/news/glp-1-agonists-show-weight-loss-and-blood-pressure-benefits-in-obesity 2026-10-23T01:27:05.597Z RetatrutideCompare en 2026-10-23T01:27:05.597Z GLP-1 Agonists Show Weight Loss and Blood Pressure Benefits in Obesity Clinical Trials, Retatrutide https://retacompare.com/news/fda-approval-anticipated-for-weight-loss-drugs-by-2026 2026-10-22T23:04:37.000Z RetatrutideCompare en 2026-10-22T23:04:37.000Z FDA Approval Anticipated for Weight Loss Drugs by 2026 Market News, Retatrutide https://retacompare.com/news/fda-raises-concerns-over-unapproved-glp-1-drugs-including-retatrutide 2026-10-22T23:03:30.000Z RetatrutideCompare en 2026-10-22T23:03:30.000Z FDA Raises Concerns Over Unapproved GLP-1 Drugs Including Retatrutide Market News, Retatrutide https://retacompare.com/news/glp-1-drugs-show-potential-in-treating-skin-conditions 2026-10-22T22:32:21.000Z RetatrutideCompare en 2026-10-22T22:32:21.000Z GLP-1 Drugs Show Potential in Treating Skin Conditions Clinical Trials, Retatrutide https://retacompare.com/news/retatrutide-reduces-kidney-stress-markers-in-obesity-and-ckd 2026-10-22T21:05:10.000Z RetatrutideCompare en 2026-10-22T21:05:10.000Z Retatrutide Reduces Kidney Stress Markers in Obesity and CKD Clinical Trials, Retatrutide https://retacompare.com/news/exploring-the-peptide-economy-beyond-glp-1-advancements 2026-10-22T20:58:29.000Z RetatrutideCompare en 2026-10-22T20:58:29.000Z Exploring the Peptide Economy Beyond GLP-1 Advancements Market News, Retatrutide https://retacompare.com/news/quality-control-essentials-for-sourcing-retatrutide-peptide 2026-10-22T16:40:44.000Z RetatrutideCompare en 2026-10-22T16:40:44.000Z Quality Control Essentials for Sourcing Retatrutide Peptide Market News, Retatrutide https://retacompare.com/news/latest-developments-in-glp-1-obesity-treatments-reported 2026-10-22T16:34:40.000Z RetatrutideCompare en 2026-10-22T16:34:40.000Z Latest Developments in GLP-1 Obesity Treatments Reported Market News, Retatrutide https://retacompare.com/news/recall-issued-for-unauthorized-glp-1-zepbound-copies 2026-10-22T15:56:47.000Z RetatrutideCompare en 2026-10-22T15:56:47.000Z Recall Issued for Unauthorized GLP-1 Zepbound Copies Market News, Retatrutide https://retacompare.com/news/recall-issued-for-imitation-glp-1-weight-loss-drug-amid-safety-concerns 2026-10-22T15:50:00.000Z RetatrutideCompare en 2026-10-22T15:50:00.000Z Recall Issued for Imitation GLP-1 Weight Loss Drug Amid Safety Concerns Market News, Retatrutide https://retacompare.com/news/exploring-glp-1-agonists-role-in-weight-loss-and-breast-cancer-risk 2026-10-22T14:11:49.000Z RetatrutideCompare en 2026-10-22T14:11:49.000Z Exploring GLP-1 Agonists' Role in Weight Loss and Breast Cancer Risk Weight Loss, Retatrutide https://retacompare.com/news/glp-1-trials-expand-to-address-alcohol-and-drug-cravings 2026-10-22T14:00:00.000Z RetatrutideCompare en 2026-10-22T14:00:00.000Z GLP-1 Trials Expand to Address Alcohol and Drug Cravings Clinical Trials, Retatrutide https://retacompare.com/news/ai-uncovers-surprises-in-unapproved-weight-loss-drug-use 2026-10-22T02:38:47.000Z RetatrutideCompare en 2026-10-22T02:38:47.000Z AI Uncovers Surprises in Unapproved Weight-Loss Drug Use Weight Loss, Retatrutide https://retacompare.com/news/latest-developments-in-retatrutide-for-weight-loss-by-2026 2026-10-22T02:30:37.000Z RetatrutideCompare en 2026-10-22T02:30:37.000Z Latest Developments in Retatrutide for Weight Loss by 2026 Market News, Retatrutide https://retacompare.com/news/new-glp-1-agonist-in-trials-retatrutide-s-potential-impact 2026-10-21T21:01:00.000Z RetatrutideCompare en 2026-10-21T21:01:00.000Z New GLP-1 Agonist in Trials: Retatrutide's Potential Impact Clinical Trials, Retatrutide https://retacompare.com/news/harvard-gazette-explores-glp-1-agonist-use-in-obesity-treatment 2026-10-21T17:15:08.000Z RetatrutideCompare en 2026-10-21T17:15:08.000Z Harvard Gazette Explores GLP-1 Agonist Use in Obesity Treatment Weight Loss, Retatrutide https://retacompare.com/news/glp-1-agonists-and-retatrutide-emerging-trends-in-obesity-treatment 2026-10-21T17:06:36.000Z RetatrutideCompare en 2026-10-21T17:06:36.000Z GLP-1 Agonists and Retatrutide: Emerging Trends in Obesity Treatment Market News, Retatrutide https://retacompare.com/news/incretin-drug-shows-potential-in-treating-sleep-apnea 2026-10-21T15:59:06.000Z RetatrutideCompare en 2026-10-21T15:59:06.000Z Incretin Drug Shows Potential in Treating Sleep Apnea Clinical Trials, Retatrutide https://retacompare.com/news/lab-tests-reveal-concerns-with-experimental-weight-loss-drug 2026-10-21T13:01:00.000Z RetatrutideCompare en 2026-10-21T13:01:00.000Z Lab Tests Reveal Concerns with Experimental Weight Loss Drug Weight Loss, Retatrutide https://retacompare.com/news/pennsylvania-medicaid-ends-coverage-for-obesity-medications 2026-10-21T12:49:00.000Z RetatrutideCompare en 2026-10-21T12:49:00.000Z Pennsylvania Medicaid Ends Coverage for Obesity Medications Market News, Retatrutide https://retacompare.com/news/gender-disparities-in-glp-1-usage-men-less-represented 2026-10-21T08:37:27.000Z RetatrutideCompare en 2026-10-21T08:37:27.000Z Gender Disparities in GLP-1 Usage: Men Less Represented Market News, Retatrutide https://retacompare.com/news/cosmetic-industry-adapts-to-changes-from-obesity-drug-use 2026-10-21T06:02:00.000Z RetatrutideCompare en 2026-10-21T06:02:00.000Z Cosmetic Industry Adapts to Changes from Obesity Drug Use Market News, Retatrutide